feed
view company updates
tools
perform investment research
network
join events & discussions
advisory
about us
Redeye Capital
Xspray: Positive clinical data for HyNap-Sora
Research Note
2019-02-18
16:21
Xspray announced positive data from a phase I pilot study, comparing the bioavailability of HyNap-Sora to Nexavar/sorafenib.
MS
Mathias Spinnars
Sign up for free to continue
Sign up with Email
Sign in with Google
Already a member?
Sign in
Disclosures and disclaimers
Premium Plan required to unlock
Unlock companies to access
more high quality research.
View Plans